Molecular Partners AG (MLLCF)
USD 4.22
(0.24%)
USD 4.22
(0.24%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -59.53 Million CHF | -148.85% |
| 2022 | 120.84 Million CHF | 297.7% |
| 2021 | -60.67 Million CHF | -10.27% |
| 2020 | -59.59 Million CHF | -68.69% |
| 2019 | -33.71 Million CHF | 9.93% |
| 2018 | -36.54 Million CHF | -50.56% |
| 2017 | -24.69 Million CHF | -33.37% |
| 2016 | -18.06 Million CHF | -1666.21% |
| 2015 | -1.02 Million CHF | -134.22% |
| 2014 | -1.47 Million CHF | -63.27% |
| 2013 | 7.93 Million CHF | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -15.25 Million CHF | 44.12% |
| 2024 Q2 | -15.37 Million CHF | -43.5% |
| 2023 Q2 | -14.19 Million CHF | -4.28% |
| 2023 Q3 | -11.69 Million CHF | 17.6% |
| 2023 FY | - CHF | -148.85% |
| 2023 Q1 | -13.61 Million CHF | 0.74% |
| 2023 Q4 | -16.04 Million CHF | -37.17% |
| 2022 Q1 | 153.26 Million CHF | 1113.5% |
| 2022 Q3 | -13.85 Million CHF | -149.33% |
| 2022 FY | - CHF | 297.7% |
| 2022 Q4 | -13.71 Million CHF | 1.02% |
| 2022 Q2 | -5.55 Million CHF | -103.63% |
| 2021 Q2 | -15.59 Million CHF | 12.68% |
| 2021 FY | - CHF | -10.27% |
| 2021 Q3 | -12.17 Million CHF | 21.94% |
| 2021 Q4 | -15.12 Million CHF | -24.2% |
| 2021 Q1 | -17.86 Million CHF | 7.35% |
| 2020 FY | - CHF | -68.69% |
| 2020 Q1 | -11.52 Million CHF | 4.05% |
| 2020 Q2 | -10.13 Million CHF | 12.09% |
| 2020 Q4 | -19.28 Million CHF | -33.4% |
| 2020 Q3 | -14.45 Million CHF | -42.68% |
| 2019 Q1 | -5.62 Million CHF | 53.81% |
| 2019 Q3 | -12.01 Million CHF | -113.64% |
| 2019 Q2 | -5.62 Million CHF | 0.0% |
| 2019 FY | - CHF | 9.93% |
| 2019 Q4 | -12.01 Million CHF | 0.0% |
| 2018 Q3 | -12.17 Million CHF | -99.5% |
| 2018 Q1 | -6.1 Million CHF | -42.2% |
| 2018 Q2 | -6.1 Million CHF | 0.0% |
| 2018 FY | - CHF | -50.56% |
| 2018 Q4 | -12.17 Million CHF | 0.0% |
| 2017 Q1 | -6.43 Million CHF | -5.13% |
| 2017 Q4 | -4.29 Million CHF | 0.0% |
| 2017 Q3 | -4.29 Million CHF | 55.97% |
| 2017 Q2 | -9.74 Million CHF | -51.39% |
| 2017 FY | - CHF | -33.37% |
| 2016 Q1 | -1.98 Million CHF | -563.47% |
| 2016 Q2 | -6.05 Million CHF | -205.63% |
| 2016 Q4 | -6.12 Million CHF | -39.76% |
| 2016 Q3 | -4.38 Million CHF | 27.63% |
| 2016 FY | - CHF | -1666.21% |
| 2015 FY | - CHF | -134.22% |
| 2015 Q4 | -298.5 Thousand CHF | -112.46% |
| 2015 Q3 | 2.39 Million CHF | 172.18% |
| 2015 Q2 | -3.31 Million CHF | -1516.86% |
| 2015 Q1 | -205.2 Thousand CHF | 22.4% |
| 2014 Q2 | 955.47 Thousand CHF | -0.0% |
| 2014 Q1 | 955.47 Thousand CHF | 0.0% |
| 2014 FY | - CHF | -63.27% |
| 2014 Q4 | -264.44 Thousand CHF | -126.29% |
| 2014 Q3 | 1 Million CHF | 5.28% |
| 2013 FY | - CHF | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.06 Million USD | -1843.509% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -1578.321% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -2505.834% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -242.717% |
| GB Sciences, Inc. | -1.41 Million USD | -4092.593% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 15813.592% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -486693.687% |
| Skye Bioscience, Inc. | -13.54 Million USD | -339.415% |
| Zenith Capital Corp. | -8.6 Million USD | -591.727% |
| Agentix Corp. | -1.37 Million USD | -4239.693% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -1432.572% |
| Biomind Labs Inc. | -1.03 Million USD | -5654.198% |
| ContraFect Corporation | -64.99 Million USD | 8.414% |
| CSL Limited | 4.78 Billion USD | 101.243% |
| CytoDyn Inc. | -18.02 Million USD | -230.19% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 885436.109% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -9313.257% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -7.573% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -16110.947% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -3775.527% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -6253.601% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 163.304% |
| SQZ Biotechnologies Company | -64.14 Million USD | 7.189% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -3902.254% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 16.197% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -2151.131% |
| Mesoblast Limited | -62.38 Million USD | 4.584% |
| Marizyme, Inc. | -34.28 Million USD | -73.651% |
| Genus plc | 73.7 Million USD | 180.773% |
| Pharming Group N.V. | 9.87 Million USD | 702.713% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -578.637% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -4146.659% |
| IMV Inc. | -35.52 Million USD | -67.58% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -2461.73% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -11391.258% |
| ONE Bio Corp. | 13.61 Million USD | 537.301% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -23.437% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 1766.573% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -1958.205% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -731.277% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -238020.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -275.116% |
| Alpha Cognition Inc. | -9.7 Million USD | -513.357% |
| Enzolytics Inc. | -2.12 Million USD | -2705.334% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 72.443% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 4991.537% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 772.367% |
| Genscript Biotech Corporation | -248.71 Million USD | 76.065% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -904.063% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -24792.327% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -2333.311% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -33719.183% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -2999.05% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -800.399% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -1215.233% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -1488.984% |
| Helix BioMedix, Inc. | -1.04 Million USD | -5589.508% |
| EV Biologics, Inc. | -1.26 Million USD | -4598.011% |
| Q BioMed Inc. | -617.62 Thousand USD | -9538.488% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -3301.716% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -50.188% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | -688.096% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -2279.333% |
| HST Global, Inc. | -5303.00 USD | -1122472.129% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -2794.02% |
| Halberd Corporation | -74.27 Thousand USD | -80043.782% |
| Resverlogix Corp. | -11.74 Million USD | -406.983% |
| Cell Source, Inc. | -4.27 Million USD | -1293.321% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -3871.563% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.11 Million USD | -873.883% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -341614.023% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -5652.819% |
| Kadimastem Ltd | -2.62 Million USD | -2168.344% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -15581.471% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -32773.52% |
| LadRx Corporation | 412.28 Thousand USD | 14539.111% |
| Regen BioPharma, Inc. | 1.46 Million USD | 4160.831% |
| Affymax, Inc. | -14.29 Million USD | -316.439% |
| Itoco Inc. | -1.86 Million USD | -3085.134% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -5234.229% |
| Mobile Lads Corp. | -2.24 Million USD | -2556.215% |
| International Stem Cell Corporation | 202 Thousand USD | 29570.297% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | -1458.317% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -75226.779% |
| Qrons Inc. | -40.08 Thousand USD | -148424.238% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -12157.092% |
| SYBLEU INC | -141.57 Thousand USD | -41949.572% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 11386.742% |
| Rebus Holdings, Inc. | -951 Thousand USD | -6159.727% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -5505.409% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -112988.906% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -2318.02% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -65.965% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -132188.889% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -2074.215% |
| Neutra Corp. | -181.24 Thousand USD | -32744.682% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -195.302% |
| PureTech Health plc | -11.62 Million USD | -411.998% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -195.323% |
| IXICO plc | -707 Thousand USD | -8320.085% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -674.626% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -23.133% |
| CSL Limited | 4.73 Billion USD | 101.258% |
| Cellectis S.A. | -92.63 Million USD | 35.738% |